Marc Frahm
Stock Analyst at TD Cowen
(0.10)
# 4,145
Out of 4,843 analysts
16
Total ratings
15.38%
Success rate
-32.83%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Marc Frahm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SANA Sana Biotechnology | Upgrades: Buy | n/a | $2.17 | - | 2 | Jan 8, 2025 | |
| TBPH Theravance Biopharma | Maintains: Hold | $10 → $9 | $9.20 | -2.17% | 3 | Aug 6, 2024 | |
| INCY Incyte | Maintains: Buy | $88 → $80 | $65.06 | +22.96% | 3 | May 1, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $8.68 | - | 1 | Jun 15, 2023 | |
| XLO Xilio Therapeutics | Initiates: Outperform | n/a | $1.07 | - | 1 | Nov 16, 2021 | |
| NUVL Nuvalent | Initiates: Outperform | n/a | $74.61 | - | 1 | Aug 23, 2021 | |
| ELEV Elevation Oncology | Initiates: Outperform | n/a | $0.30 | - | 1 | Jul 20, 2021 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $23.80 | - | 1 | Jul 6, 2021 | |
| DAWN Day One Biopharmaceuticals | Initiates: Outperform | n/a | $6.38 | - | 1 | Jun 21, 2021 | |
| INZY Inozyme Pharma | Initiates: Outperform | n/a | $3.97 | - | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.20 | - | 1 | Feb 24, 2020 |
Sana Biotechnology
Jan 8, 2025
Upgrades: Buy
Price Target: n/a
Current: $2.17
Upside: -
Theravance Biopharma
Aug 6, 2024
Maintains: Hold
Price Target: $10 → $9
Current: $9.20
Upside: -2.17%
Incyte
May 1, 2024
Maintains: Buy
Price Target: $88 → $80
Current: $65.06
Upside: +22.96%
Cullinan Therapeutics
Jun 15, 2023
Initiates: Outperform
Price Target: n/a
Current: $8.68
Upside: -
Xilio Therapeutics
Nov 16, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.07
Upside: -
Nuvalent
Aug 23, 2021
Initiates: Outperform
Price Target: n/a
Current: $74.61
Upside: -
Elevation Oncology
Jul 20, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.30
Upside: -
Janux Therapeutics
Jul 6, 2021
Initiates: Outperform
Price Target: n/a
Current: $23.80
Upside: -
Day One Biopharmaceuticals
Jun 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $6.38
Upside: -
Inozyme Pharma
Aug 18, 2020
Initiates: Outperform
Price Target: n/a
Current: $3.97
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.20
Upside: -